

§ 1.136(a), and any fees required therefor (including fees for net addition of claims) are hereby authorized to be charged to our Deposit Account No. 19-0036.

Amendments

In the Claims:

Please substitute the following claim 1 for pending claim 1:

1. (thrice amended) A composition comprising an inhibitor of human osteonectin and a pharmaceutically acceptable carrier, wherein said inhibitor has an activity selected from the group consisting of: preventing expression of human osteonectin in tumour cells and decreasing expression of human osteonectin in tumour cells, and wherein said inhibitor comprises an antisense polynucleotide which binds to osteonectin mRNA so as to prevent or decrease expression of human osteonectin by preventing or decreasing translation of said mRNA into human osteonectin.

Please substitute the following claim 6 for pending claim 6:

6. (twice amended) The composition according to Claim 1, wherein said antisense polynucleotide is an antisense RNA complimentary to human osteonectin mRNA.

Please add the following new claims:

OK To
Enter
3/27/02
mms

37. (New) The composition of claim 1, wherein said composition is a pharmaceutical composition.

38. (New) The vector of claim 25, wherein the vector is a plasmid containing a cytomegalovirus promoter.